This is a preview of subscription content, log in via an institution to check access.
References
Greenberg SM, Bacskai BJ, Hernandez-Guillamon M et al (2020) Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways. Nat Rev Neurol. https://doi.org/10.1038/s41582-019-0281-2
Chételat G, Arbizu J, Barthel H et al (2020) Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer’s disease and other dementias. Lancet Neurol. https://doi.org/10.1016/S1474-4422(20)30314-8
Kantarci K, Lowe VJ, Chen Q et al (2020) β-Amyloid PET and neuropathology in dementia with Lewy bodies. Neurology. https://doi.org/10.1212/WNL.0000000000008818
Haller S, Jäger HR, Vernooij MW et al (2023) Neuroimaging in dementia: more than typical Alzheimer disease. Radiology. https://doi.org/10.1148/radiol.230173
Charidimou A, Boulouis G, Frosch MP et al (2022) The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI–neuropathology diagnostic accuracy study. Lancet Neurol. https://doi.org/10.1016/S1474-4422(22)00208-3
Yamada M, Komatsu J, Nakamura K et al (2020) Diagnostic criteria for dementia with lewy bodies: updates and future directions. J Mov Disord. https://doi.org/10.14802/jmd.19052
Koemans EA, Chhatwal JP, van Veluw AJ et al (2023) Progression of cerebral amyloid angiopathy: a pathophysiological framework. Lancet Neurol. https://doi.org/10.1016/S1474-4422(23)00114-X
Altomare D, Barkhof F, Caprioglio C et al (2023) Clinical effect of early vs late amyloid positron emission tomography in memory clinic patients. The AMYPAD-DPMS randomized clinical trial. JAMA Neurol. https://doi.org/10.1001/jamaneurol.2023.0997
Ossenkoppele R, Pichet Binette A, Groot C et al (2022) Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat Med. https://doi.org/10.1038/s41591-022-02049-x
Kantarci K, Murray ME, Schwarz CG et al (2017) White-matter integrity on DTI and the pathologic staging of Alzheimer’s disease. Neurobiol Aging. https://doi.org/10.1016/j.neurobiolaging.2017.04.024
Charidimou A, Krishnan A, Werring DJ et al (2013) Cerebral microbleeds: a guide to detection and clinical relevance in different disease settings. Neuroradiology. https://doi.org/10.1007/s00234-013-1175-4
Auriel E, Charidimou A, Gurol ME et al (2016) Validation of clinicoradiological criteria for the diagnosis of cerebral amyloid angiopathy–related inflammation. JAMA Neurol. https://doi.org/10.1001/jamaneurol.2015.4078
Cogswell PM, Barakos JA, Barkhof F et al (2022) Amyloid-related imaging abnormalities with emerging Alzheimer disease therapeutics: detection and reporting recommendations for clinical practice. AJNR Am J Neuroradiol. https://doi.org/10.3174/ajnr.A7586
Funding
The author states that this work has not received any funding.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Guarantor
The scientific guarantor of this publication is Prof. Hans Rolf Jäger.
Conflict of interest
The author of this manuscript declares no relationships with any companies, whose products or services may be related to the subject matter of the article.
Statistics and biometry
No complex statistical methods were necessary for this paper.
Informed consent
Written informed consent was not required.
Ethical approval
Institutional Review Board approval was not required because this is an invited commentary.
Study subjects or cohorts overlap
Not applicable
Methodology
• commentary
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Jäger, H.R. The connection between cerebral amyloid angiopathy and Alzheimer’s disease. Eur Radiol 34, 2171–2173 (2024). https://doi.org/10.1007/s00330-023-10462-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-023-10462-0